Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...

Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

The report, spearheaded by analyst Larry Biegelsen, pointed to conversations with physicians and industry contacts indicating that Johnson & Johnson has possibly paused Varipulse procedures because of ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.